Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA
» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:MRK, NYSE:PFE, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:BMY, OTCPK:BAYRY, NYSE:LLY, NYSE:AZN, NYSE:JNJ, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVS.USA,
Novartis AG is engaged in the research, development, manufacturing and marketing of healthcare products and pharmaceuticals.

Novartis AG was incorporated on February 29, 1996 under the laws of Switzerland as a stock corporation (Aktiengesellschaft) with an indefinite duration. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. It is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of healthcare products led by innovative pharmaceuticals. Its broad portfolio includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines and eye care devices. It operates in the following segments: Innovative Medicines (formerly named Pharmaceuticals): Innovative patent-protected prescription medicines; Sandoz: Generic pharmaceuticals and biosimilars; and Alcon: Surgical and vision care products.

Ratios

vs
industry
vs
history
PE Ratio 28.22
NVSEF's PE Ratio is ranked lower than
52% of the 453 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.06 vs. NVSEF: 28.22 )
Ranked among companies with meaningful PE Ratio only.
NVSEF' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.96 Max: 29.97
Current: 28.22
5.7
29.97
Forward PE Ratio 16.13
NVSEF's Forward PE Ratio is ranked lower than
53% of the 88 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.82 vs. NVSEF: 16.13 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.22
NVSEF's PE Ratio without NRI is ranked lower than
52% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.19 vs. NVSEF: 28.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVSEF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.24 Max: 31.15
Current: 28.22
10.63
31.15
Price-to-Owner-Earnings 16.94
NVSEF's Price-to-Owner-Earnings is ranked higher than
76% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.27 vs. NVSEF: 16.94 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVSEF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 15.71 Max: 23.92
Current: 16.94
7.18
23.92
PB Ratio 2.42
NVSEF's PB Ratio is ranked higher than
57% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. NVSEF: 2.42 )
Ranked among companies with meaningful PB Ratio only.
NVSEF' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.44 Max: 3.95
Current: 2.42
1.69
3.95
PS Ratio 3.82
NVSEF's PS Ratio is ranked lower than
62% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. NVSEF: 3.82 )
Ranked among companies with meaningful PS Ratio only.
NVSEF' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.27 Max: 5.01
Current: 3.82
1.89
5.01
Price-to-Free-Cash-Flow 22.97
NVSEF's Price-to-Free-Cash-Flow is ranked lower than
52% of the 185 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.92 vs. NVSEF: 22.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVSEF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.05  Med: 17.11 Max: 26.68
Current: 22.97
7.05
26.68
Price-to-Operating-Cash-Flow 16.42
NVSEF's Price-to-Operating-Cash-Flow is ranked lower than
52% of the 233 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.34 vs. NVSEF: 16.42 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVSEF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.77  Med: 13.26 Max: 19.3
Current: 16.42
5.77
19.3
EV-to-EBIT 22.52
NVSEF's EV-to-EBIT is ranked lower than
57% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.61 vs. NVSEF: 22.52 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 26.4
Current: 22.52
8.5
26.4
EV-to-EBITDA 13.03
NVSEF's EV-to-EBITDA is ranked higher than
64% of the 478 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.32 vs. NVSEF: 13.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVSEF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18
Current: 13.03
7.3
18
PEG Ratio 7.23
NVSEF's PEG Ratio is ranked lower than
85% of the 266 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. NVSEF: 7.23 )
Ranked among companies with meaningful PEG Ratio only.
NVSEF' s PEG Ratio Range Over the Past 10 Years
Min: 0.36  Med: 2.01 Max: 24.74
Current: 7.23
0.36
24.74
Shiller PE Ratio 16.14
NVSEF's Shiller PE Ratio is ranked higher than
90% of the 157 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.81 vs. NVSEF: 16.14 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVSEF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.68  Med: 14.69 Max: 21.57
Current: 16.14
9.68
21.57
Current Ratio 1.12
NVSEF's Current Ratio is ranked lower than
82% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. NVSEF: 1.12 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.4 Max: 2.83
Current: 1.12
0.96
2.83
Quick Ratio 0.84
NVSEF's Quick Ratio is ranked lower than
80% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NVSEF: 0.84 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.17 Max: 2.48
Current: 0.84
0.7
2.48
Days Inventory 135.81
NVSEF's Days Inventory is ranked lower than
59% of the 567 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.74 vs. NVSEF: 135.81 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 135.81
117.82
183.45
Days Sales Outstanding 62.61
NVSEF's Days Sales Outstanding is ranked higher than
64% of the 507 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.21 vs. NVSEF: 62.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 62.61
56.31
70.59
Days Payable 104.96
NVSEF's Days Payable is ranked higher than
71% of the 471 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.12 vs. NVSEF: 104.96 )
Ranked among companies with meaningful Days Payable only.
NVSEF' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 104.96
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.49
NVSEF's Dividend Yield % is ranked higher than
91% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. NVSEF: 3.49 )
Ranked among companies with meaningful Dividend Yield % only.
NVSEF' s Dividend Yield % Range Over the Past 10 Years
Min: 1.49  Med: 3.35 Max: 5.11
Current: 3.49
1.49
5.11
Dividend Payout Ratio 0.95
NVSEF's Dividend Payout Ratio is ranked higher than
70% of the 378 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. NVSEF: 0.95 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVSEF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.97
Current: 0.95
0.4
0.97
3-Year Dividend Growth Rate 7.60
NVSEF's 3-Year Dividend Growth Rate is ranked lower than
54% of the 270 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.20 vs. NVSEF: 7.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVSEF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.15 Max: 18.5
Current: 7.6
0
18.5
Forward Dividend Yield % 3.55
NVSEF's Forward Dividend Yield % is ranked higher than
87% of the 612 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVSEF: 3.55 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.50
NVSEF's 5-Year Yield-on-Cost % is ranked higher than
87% of the 771 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. NVSEF: 4.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVSEF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.92  Med: 4.32 Max: 6.58
Current: 4.5
1.92
6.58
3-Year Average Share Buyback Ratio 0.70
NVSEF's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. NVSEF: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVSEF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.45
NVSEF's Price-to-Tangible-Book is ranked lower than
91% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. NVSEF: 14.45 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVSEF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 5.26 Max: 35.21
Current: 14.45
2.68
35.21
Price-to-Intrinsic-Value-Projected-FCF 1.24
NVSEF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.61 vs. NVSEF: 1.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVSEF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.16 Max: 2.39
Current: 1.24
0.76
2.39
Price-to-Median-PS-Value 1.17
NVSEF's Price-to-Median-PS-Value is ranked higher than
52% of the 538 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.22 vs. NVSEF: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVSEF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.12 Max: 1.61
Current: 1.17
0.72
1.61
Price-to-Graham-Number 4.18
NVSEF's Price-to-Graham-Number is ranked lower than
82% of the 331 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. NVSEF: 4.18 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVSEF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.24  Med: 2.48 Max: 6.59
Current: 4.18
1.24
6.59
Earnings Yield (Greenblatt) % 4.40
NVSEF's Earnings Yield (Greenblatt) % is ranked higher than
58% of the 611 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. NVSEF: 4.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVSEF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.8  Med: 6.4 Max: 11.8
Current: 4.4
3.8
11.8
Forward Rate of Return (Yacktman) % 4.73
NVSEF's Forward Rate of Return (Yacktman) % is ranked lower than
58% of the 353 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.48 vs. NVSEF: 4.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVSEF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 13.8 Max: 61.6
Current: 4.73
1
61.6

More Statistics

Revenue (TTM) (Mil) $49,436
EPS (TTM) $ 2.80
Beta0.84
Short Percentage of Float0.00%
52-Week Range $66.35 - 83.80
Shares Outstanding (Mil)2,374.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,460 52,434 54,894
EPS ($) 4.77 5.26 5.84
EPS without NRI ($) 4.77 5.26 5.84
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.38%
Dividends per Share ($) 2.85 3.03 3.18
» More Articles for OTCPK:NVSEF

Headlines

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Novartis Has Bright Future Feb 01 2017 
2 Top Health Care Dividend Stocks Jan 12 2017 
7 Stocks With Low P/S Ratios Jan 11 2017 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
The Pharmaceutical Sector Looks Attractive Oct 12 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Novartis Is Surviving Oct 03 2016 

More From Other Websites
Novartis wins CHMP nod for drug combo against some lung cancers Feb 24 2017
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs Feb 24 2017
[$$] Big pharma bets billions on 'silent' liver disease Feb 21 2017
Bristol-Myers: Don't Bet on a Pfizer Acquisition Feb 15 2017
4Q16 Performance of GlaxoSmithKline’s Business Segments Feb 14 2017
Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education Feb 14 2017
Novartis’s Valuation after the 4Q16 Results Feb 03 2017
Why the Majority of Analysts Deem Novartis a ‘Buy’ Feb 03 2017
Novartis’s Financial Guidance and Priorities for 2017 Feb 03 2017
Novartis’s Recent Developments Feb 02 2017
Novartis (NVS) Votubia Gets EU Approval for Label Expansion Feb 02 2017
Inside Novartis’s Eye Care Performance in 4Q16 Feb 02 2017
Novartis Has Bright Future Feb 01 2017
Novartis’s Innovative Medicines Segment in 4Q16 Feb 01 2017
Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16 Feb 01 2017
Novartis’s 4Q16 Earnings Meet Analysts’ Estimates Feb 01 2017
Novartis Considers Alcon Spin-Off Jan 31 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK